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Introduction {#sec1}
============

Argininosuccinate lyase (ASL) is a urea cycle enzyme that facilitates the conversion of excess nitrogen to urea in the liver. In extrahepatic tissues, ASL participates in the citrulline-arginine cycle to support the cellular requirement for arginine ([@bib43]). In fact, ASL is the only enzyme in mammals that generates arginine although five other enzymes use arginine as a substrate for the synthesis of nitric oxide (NO), polyamines, agmatine, creatine, proline, and glutamate, all of which are essential for cell survival, growth, and proliferation ([@bib43]). Loss of ASL would thus be predicted to affect multiple physiological processes. This is best illustrated by the complex phenotype observed in individuals with argininosuccinic aciduria or ASL deficiency (ASLD), a urea cycle disorder that is caused by germline, loss-of-function, pathogenic variants in *ASL* ([@bib4], [@bib17], [@bib42], [@bib45], [@bib47], [@bib56]). In spite of having fewer episodes of hyperammonemia as compared to individuals with other urea cycle disorders (UCDs), individuals with ASLD are at increased risk to develop intellectual and learning disabilities, behavioral abnormalities, epilepsy, ataxia, and hypertension ([@bib5], [@bib10], [@bib20], [@bib31], [@bib33], [@bib39], [@bib55]). Thus, pathogenic mechanisms other than hyperammonemia likely contribute to the phenotypes observed in ASLD.

We have previously reported that ASL is an essential regulator of systemic and tissue-specific NO production. Because of the structural necessity of ASL for the formation of a NO-synthesis complex, supplementation with arginine is not sufficient to replenish NO levels ([@bib18]). Treatment with pharmacologic precursors of NO rather than arginine have been shown to increase survival and correct hypertension in a murine model of ASLD. Interestingly, a patient with ASLD treated with NO supplements for hypertension also demonstrated beneficial effects on verbal memory and nonverbal problem solving ([@bib46]). Nitric oxide is a signaling molecule, which acts as messenger for multiple pathways in different tissues. In the CNS, NO has a role in various physiologic processes, including brain development, regulation of synaptic plasticity, and behavioral and physiology homeostasis ([@bib9], [@bib11], [@bib26]). Specifically, in the locus coeruleus (LC), NO is involved in synaptic transmission and the modulation of neuronal spiking and energy stability ([@bib50], [@bib60]). In the context of these data, our aim was to understand the role of ASL and NO in the neurological phenotype in ASLD, as well as in neurobehavioral and cognitive functions.

Results {#sec2}
=======

ASL Is Highly Expressed in the Locus Coeruleus and Regulates TH Levels {#sec2.1}
----------------------------------------------------------------------

To understand the roles of ASL in the brain, we first determined the distribution of ASL using *in situ* hybridization (ISH) and immunostaining in coronal sections of brain obtained from wild-type mice. Consistent with previous reports, we found sparse expression of ASL in different brain regions ([@bib5], [@bib8]); however, we found a prominent expression in the LC nuclei ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}). In brainstem sections from mice as well as in brain tissue array from humans, we find ASL expression to distinctly co-localize with tyrosine hydroxylase (TH) expression, the gold standard for marking the LC region ([Figures 1](#fig1){ref-type="fig"}B and 1C). Interestingly, ASL expression in specific dopaminergic regions was faint (data not shown). To understand the role of ASL in the LC, we generated an ASL-LC conditional knockout (cKO) mouse by breeding *Asl*^*f/f*^ mice with mice overexpressing Cre recombinase under the *TH* promoter (*Asl*^*f/f*^*;TH Cre*^*+/−*^) ([Figure 1](#fig1){ref-type="fig"}D). Using laser microdissections, we performed RNA sequencing, specifically on LC neurons collected from *Asl*^*f/f*^ control and *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). Our analysis revealed prominent differences in pathways related to the stimulation and release of neurotransmitters from neurons, especially from the catecholamine nuclei ([Figure S2](#mmc1){ref-type="supplementary-material"}B; [Table S2](#mmc3){ref-type="supplementary-material"}). Interestingly, *TH* was among the most significantly differently expressed genes between the LC of *Asl*^*f/f*^ control and *Asl*^*f/f*^ *;TH Cre*^*+/−*^ mice, both at the mRNA and protein levels ([Figures 1](#fig1){ref-type="fig"}E--1G; [Table S3](#mmc4){ref-type="supplementary-material"}). Notably, the decrease in TH was specific to *Asl*^*f/f*^ *;TH Cre*^*+/−*^ mice and was not present in transgenic *TH Cre*^*+/−*^ control mice ([Figure S2](#mmc1){ref-type="supplementary-material"}C).Figure 1ASL Is Highly Expressed in the LC and Regulates TH Levels(A) Left: *in situ* hybridization with *Asl* anti-sense mRNA probe showing in purple *Asl* prominent expression in the LC. Right: scheme of brain stem coronal section is shown. LC region is highlighted in purple (image adapted from The Mouse Brain Atlas).(B) Immunostaining of mouse brainstem for Asl (left, red), TH (center, green), and their merged co-localization (right).(C) Immunostaining of human brainstem for ASL (left, red), TH (center, green), and their merged co-localization (right).(D and E) Quantification of *Asl* mRNA (D) and *TH* mRNA (E) isolated by laser microdissection from the LC of *Asl*^*f/f*^*;TH Cre*^*+/−*^ and from *Asl*^*f/f*^ control mice as measured by RT-PCR with specific TaqMan probes (n = 100 cells from 7 animals).(F) Immunohistochemistry quantification of TH protein normalized to cells number (n = 4 in each group).(G) Quantification of western blots for TH levels in LC regions taken by punch biopsies (n = 4 in each group).The bottom panels of (F) and (G) show representative images for each detection method, respectively.Data represent mean ± SEM (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001; ns, not significant). See [Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"} for RNA sequencing, ingenuity pathway analysis, and proteomic analysis, respectively.

ASL Deficiency in Catecholamine Neurons Decreases Protein Nitrosylation {#sec2.2}
-----------------------------------------------------------------------

Because ASL has been shown to regulate NO synthesis ([@bib18]), we hypothesized that the reduction in TH levels in *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice is caused by NO deficiency. We hence generated mice in which the LC neurons were labeled by the red florescence protein (RFP) dTomato (*Asl*^*f/f*^*,Ai9*^*f/f*^*;TH Cre*^*+/−*^). Using flow cytometry, we found significantly lower NO levels in noradrenergic neurons of *Asl*^*f/f*^*,Ai9*^*f/f*^*;TH Cre*^*+/−*^ mice in comparison to *Ai9*^*f/f*^*;TH Cre*^*+/−*^ control mice, although the RFP level did not differ between the groups ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A).Figure 2ASL Regulates TH Levels by Regulating NO Availability(A) NO levels measurement using DAF-FM probe demonstrates significantly reduced NO levels in the LC of *Asl*^*f/f*^*,Ai9*^*f/f*^*;TH Cre*^*+/−*^ mice as compared to *Ai9*^*f/f*^*;TH Cre*^*+/−*^ control mice (each experiment was performed with pair of control and *Asl*^*f/f*^*,Ai9*^*f/f*^*;TH Cre*^*+/−*^ mice; n = 3).(B) Knockdown of *ASL* in SH-SY5Y neurons using three different lentiviral *ASL-shRNA* clones associates with downregulation in *TH* mRNA levels.(C) *shASL* SH-SY5Y neurons have significantly reduced nitrosylation of GAPDH (left) and of TH (right; measurement was performed ≥3 times).(D) NO donors' supplementation to SH-SY5Y neurons rescues the differences in GAPDH (left) and TH (right) nitrosylation between *shASL* and *shGFP* control neurons.(E) Treatment of *shASL* neurons with NO donors normalizes *TH* mRNA levels to that of *shGFP* control neurons (n ≥ 3; one-way ANOVA with Bonferroni).Data represent mean ± SEM (^∗^p \< 0.05; ^∗∗^p \< 0.01). See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To evaluate the functional consequences of ASL and NO depletion on catecholamine neurons, we used the human neuroblastoma SH-SY5Y cells, which express both ASL and the proteins required for catecholamine synthesis. Following differentiation of SH-SY5Y cells to noradrenergic-like neurons with secretory activity ([@bib38]), we downregulated ASL expression using *shRNA* targeting *ASL* ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Corroborating the *in vivo* results, we found a significant downregulation of *TH* levels in differentiated SH-SY5Y neurons with *ASL* downregulation, as compared to *shGFP* control cells ([Figure 2](#fig2){ref-type="fig"}B). NO regulates its downstream effects, in part by protein nitrosylation, a post-translational covalent modification known to regulate protein activity ([@bib23]). Specifically, nitrosylation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) affects the DNA binding ability of cyclic AMP (cAMP) response element-binding protein (CREB). CREB is one of the main transcription factors that regulate TH expression and its downstream effects ([@bib27], [@bib54], [@bib61]). GAPDH nitrosylation and expression of other CREB target genes (e.g., *cFOS* and *VGF*) were reduced in SH-SY5Y *shASL* neurons as compared to *shGFP* controls ([Figures 2](#fig2){ref-type="fig"}C, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E). In addition, direct nitrosylation of TH, which has been established to enhance its enzymatic activity ([@bib58]), was also significantly reduced in *shASL* neurons ([Figures 2](#fig2){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}D). Supplementing SH-SY5Y *shASL* neurons with NOS-independent NO donor normalized nitrosylation of both GAPDH and TH and increased *TH* mRNA levels similar to that of *shGFP* control neurons ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S3](#mmc1){ref-type="supplementary-material"}F). Together, these results suggest that, following loss of ASL, the reduction in NO levels leads to reduced TH transcription and activity.

Decreased TH Is Associated with Impaired Catecholamine Synthesis {#sec2.3}
----------------------------------------------------------------

To test whether the downregulation of TH is functionally significant, we next examined catecholamine levels in LC of *Asl*^*f/f*^*;TH Cre*^*+/−*^ and *Asl*^*f/f*^ control mice. Analysis of the neurochemical data showed that *Asl*^*f/f*^*;TH Cre*^*+/−*^ had decreased norepinephrine and dopamine levels ([Figure 3](#fig3){ref-type="fig"}A). Because clinical manifestations as attention deficits and anxiety related to LC pathogenicity have been shown to involve an abnormal catecholamine release in response to stress ([@bib41]), we measured catecholamine levels following stressful stimuli. Following acute stress provocation, dopamine levels were significantly decreased, and its turnover rates were significantly upregulated in LC of *Asl*^*f/f*^*;TH Cre*^*+/−*^ in comparison to *Asl*^*f/f*^ controls. Norepinephrine levels did not differ between *Asl*^*f/f*^*;TH Cre*^*+/−*^ and control mice following the stressful stimuli, likely because the majority of norepinephrine containing neural terminals are outside of the LC ([Figure 3](#fig3){ref-type="fig"}A). Indeed, the dependence of norepinephrine availability on ASL expression in the LC was clearly seen in the hippocampus, a target region for LC projections. During acute stress, significant elevations in norepinephrine levels were observed in the hippocampus in *Asl*^*f/f*^ control, but not in *Asl*^*f/f*^*;TH Cre*^*+/−*^, mice ([Figure 3](#fig3){ref-type="fig"}B). Importantly, treatment with NO donors normalized norepinephrine levels in the LC ([Figure 3](#fig3){ref-type="fig"}C). Thus, noradrenergic transmission in *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice facilitates NO-dependent reduced response in the LC.Figure 3ASL Deficiency Associates with Decreased Catecholamine Synthesis(A) Measurement of LC catecholamine levels show alterations in quantity and in turnover rates in both dopamine (left) and in norepinephrine (right), in *Asl*^*f/f*^*;TH Cre*^*+/−*^ as compared to *Asl*^*f/f*^ control mice (n ≥ 10 mice in each group).(B) Measurements of norepinephrine levels in the hippocampus following stress show decreased elevation in *Asl*^*f/f*^*;TH Cre*^*+/−*^ as compared to *Asl*^*f/f*^ control mice (n ≥ 9 mice in each group).(C) Measurements of LC norepinephrine levels of mice treated with NaNO~2~ show no difference between *Asl*^*f/f*^*;TH Cre*^*+/−*^ and *Asl*^*f/f*^ control mice (n ≥ 5 mice in each group).Data represent mean ± SEM (non-repeated-measures two-way ANOVA with Bonferroni post hoc t tests; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001).

LC-ASL cKO Neurons Have Impaired Firing Rate {#sec2.4}
--------------------------------------------

The functional consequences of reduction in TH expression and in norepinephrine availability was further evaluated by recording LC neuronal activity in brainstem slices obtained from *Asl*^*f/f*^ control and *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice. We found that LC neurons in slices from *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice demonstrate a spontaneous action potential firing activity that was more frequent when compared to *Asl*^*f/f*^ control mice ([Figures 4](#fig4){ref-type="fig"}A--4C). The distributions of inter-spike intervals fitted with the normal gamma distribution ([Figure 4](#fig4){ref-type="fig"}B). Passive properties of LC neurons, as well as spike shape properties, were not significantly different between the groups, all except for the after-hyperpolarization recovery slope ([Figures 4](#fig4){ref-type="fig"}D--4F). We found the maximal slope to be significantly sharper in *Asl*^*f/f*^*;TH Cre*^*+/−*^ neurons than *Asl*^*f/f*^ control. In *Asl*^*f/f*^*;TH Cre*^*+/−*^, this slope showed significant correlation with average firing frequency, which links the spike shape properties to firing rate ([Figures 4](#fig4){ref-type="fig"}D--4F). Collectively, these results support that reduced TH activity following ASL loss alters neuronal function in the LC.Figure 4ASL Deficiency in the LC Associates with Increased Firing from LC Neurons(A) Representative recordings of spontaneous action potentials of LC neurons. Upper panel ---*Asl*^*f/f*^ control, showing typical inter-spike interval variability; lower panel---*Asl*^*f/f*^*;TH Cre*^*+/−*^ (frequency 7.9 ± 0.6 Hz in *Asl*^*f/f*^ control; 13.8 ± 2.0 Hz in *Asl*^*f/f*^*;TH Cre*^*+/−*^; p \< 0.01).(B) Averaged normalized inter-spike interval (ISI) histograms. (Left) *Asl*^*f/f*^ control n = 14 is shown; (right) *Asl*^*f/f*^*;TH Cre*^*+/−*^ n = 15 cells are shown; red, gamma distribution probability density function fit with shape parameters 26 and 60 and scale parameters 5.9 and 1.7, respectively. ISI distributions from single recordings were also fit with gamma distribution (data not shown) with shape parameters 31 ± 6 and 122 ± 37 (p \< 0.03) and scale parameters 8.4 ± 2.7 and 2.4 ± 0.8 (p \< 0.04) in *Asl*^*f/f*^ control and *Asl*^*f/f*^*;TH Cre*^*+/−*^, respectively.(C) Spiking frequency presented as mean ISI (left; 144 ± 17 ms in *Asl*^*f/f*^ control \[n = 14 cells from 3 animals\] and 93 ± 13 ms in *Asl*^*f/f*^*;TH Cre*^*+/−*^ \[n = 15 cells from 3 animals\] p \< 0.03) and SEM. ISI as a measure of ISI variability (right; SEM ISI 33 ± 6 ms in *Asl*^*f/f*^ control and 14 ± 3 ms in *Asl*^*f/f*^*;TH Cre*^*+/−*^; p \< 0.02).(D) Examples for averaged spike (first 10 spikes from a recording per cell), showing the "landmarks" used for analyzing the spike shape (red asterisks: spike threshold; spike peak; and after-hyperpolarization). Red line, AHP recovery slope.(E) Firing frequency and after-hyperpolarization (AHP) recovery slope scatterplot and per-cell linear regression plot: Ct ● y = 15x + 5; r2 = 0.25; dashed line; cKO ♦ y = 61x − 2; r2 = 0.79; solid line.(F) After hyperpolarization current properties; left to right, amplitude (ahpAmpl −19.5 ± 0.7 mV n = 13 and −19.0 ± 1.0 mV n = 14; n.s.) and recovery slope (ahpSlope 0.18 ± 0.01 mV/ms n = 13 and 0.23 ± 0.02 mV/ms n = 14; p \< 0.05). In *Asl*^*f/f*^*;TH Cre*^*+/−*^ group, this slope is correlated with firing frequency (data not shown; correlation coefficient 0.79; p \< 0.001; Pearson correlation), whereas in the *Asl*^*f/f*^ control cells, this correlation was not observed (0.25; p = 0.41). Other passive and active properties of LC neurons were not significantly different between the groups (data not shown; resting membrane potential −48.9 ± 0.7 mV n = 12 and −48.6 ± 0.9 mV n = 15; input resistance 113 ± 7 MOhm n = 13 and 121 ± 11 MOhm n = 15; spike threshold −39.8 ± 0.9 mV n = 12 and −38.6 ± 1.0 mV n = 15; spike amplitude 83.1 ± 2.2 mV n = 14 and 86.1 ± 2.5 mV n = 15; spike width 2.09 ± 0.08 ms n = 14 and 2.04 ± 0.06 ms n = 15 in *Asl*^*f/f*^ control and *Asl*^*f/f*^*;TH Cre*^*+/−*^, respectively).

Phenotypic Consequences of ASL Deficiency in LC {#sec2.5}
-----------------------------------------------

Deregulation of LC has been strongly associated with attention problems in murine models as well as humans ([@bib14], [@bib30], [@bib34], [@bib53]). Thus, we first assessed whether individuals with ASLD are at risk for attention problem by using data from the Longitudinal Study of UCDs conducted by the Urea Cycle Disorders Consortium. From this dataset, we analyzed the parent- or participant-reported behavioral characteristics in individuals with ASLD in comparison to patients with argininosuccinate synthase deficiency (ASS1D), the urea cycle enzyme upstream of ASL. This analysis demonstrated that short attention span was reported at least during one study visit, in 55% of individuals with ASLD as compared to 39.4% with ASS1D ([Figure S4](#mmc1){ref-type="supplementary-material"}A). As hyperammonemia can be a confounder for any behavioral outcomes in UCDs, we further evaluated the prevalence of self-reported short attention span in individuals who did not have any documented episodes of hyperammonemia. Even in the absence of documented hyperammonemia, 54% of individuals with ASLD reported short attention span, whereas the percentage in ASS1D was now 18% ([Figure S4](#mmc1){ref-type="supplementary-material"}A). These provide a human context to the findings that some of the behavioral abnormalities in ASLD are due to cell-autonomous loss of ASL in the neurons. To validate these observations further, we compared attention problem scores on the Child Behavior Checklist (CBCL) reported in participants with ASLD and ASS1D using longitudinal quantile regression models. The standardized scores for the CBCL attention problems for individuals with ASLD and ASS1D were both within the pathological clinical range (i.e., decreased attention) when compared to the normative population ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

As LC is critically involved in orchestrating the central stress responses involving cardiovascular and stereotypical manifestations ([@bib15], [@bib48], [@bib51]), we wanted to explore whether LC loss of ASL could contribute to the hypertension observed in mice and humans with ASLD. Using continuous blood pressure telemetric measurements, and consistent with our previous reports, we found that endothelial-ASL cKO mice (*Asl*^*f/f*^*;Cdn Cre*^*+/−*^) have a significantly higher blood pressure ([@bib31]). In contrast, LC-ASL cKO mice (*Asl*^*f/f*^*;TH Cre*^*+/−*^) demonstrated blood pressure and heart rate that were comparable to their control littermates ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). To evaluate whether loss of LC-ASL alters the hemodynamic responses to stress, we performed continued telemetry monitoring with the induction of acute psychological stress. As expected, immediately following the intruder stress, both *Asl*^*f/f*^ control and *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice displayed an increase in blood pressure ([Figure 5](#fig5){ref-type="fig"}A). However, *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice had a three-fold increase in blood pressure levels as compared to controls ([Figure 5](#fig5){ref-type="fig"}A). Moreover, for 3 h following stress induction, *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice continued to have a higher blood pressure. Additionally, they required a longer recovery time to normalize blood pressure levels ([Figures 5](#fig5){ref-type="fig"}A and 5B). Interestingly, although the endothelial-ASL cKO mice have baseline hypertension, following stress induction their blood pressure elevation did not differ from that of *Asl*^*f/f*^ control mice ([Figure 5](#fig5){ref-type="fig"}A).Figure 5Phenotypic Consequences of ASL Deficiency in LC(A) Measured mean arterial pressure (MAP) levels following induction of acute stress by exposure to intruder mice. The increase in blood pressure levels following stress is higher in *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice and requires a longer recovery time as compared to *Asl*^*f/f*^ control and to endothelial-ASL cKO mice (n ≥ 8 in each group; repeated-measures two-way ANOVA with Holm-Sidak's post hoc t tests).(B) Continuous blood pressure measurement during the first 3 h after stress induction demonstrates a significantly higher blood pressure in *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice as compared to *Asl*^*f/f*^ control mice (n ≥ 8 in each group).(C and D) Open-field test locomotor evaluation. Following stressful stimuli, *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice present increase locomotor activity as indicated in distance (C) and speed (D), in comparison to *Asl*^*f/f*^ control mice. Following treatment with NO donors, *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice response to stressful stimuli is similar to that of *Asl*^*f/f*^ control mice (n ≥ 11 in each group; non-repeated-measures two-way ANOVA with Bonferroni post hoc t tests).(E) Seizure score after injection of 50 mg/kg PTZ is higher in *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice as compared to *Asl*^*f/f*^ control mice. Following treatment with NO donor, there was no significant difference in the seizure reaction to injection between the two genotypes (n = 6 in each group).(F) Kaplan Meier estimator presenting the probability of mice to develop myoclonic jerks from the time of PTZ injection. *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice have more than 4-fold chance of developing myoclonic jerks as compared to *Asl*^*f/f*^ control mice.Data represent mean ± SEM (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001). See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To evaluate the effect ASL loss has on LC-related stereotypical behaviors, we examined the responses to restrain-stress stimuli in *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice by performing the open-field test. Although analysis of the locomotor activity parameters between genotypes showed no differences during non-stress state ([Figure S4](#mmc1){ref-type="supplementary-material"}E), following acute stress exposure, *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice exhibited abnormal locomotor activity as reflected by increase in both distance traveled and speed ([Figures 5](#fig5){ref-type="fig"}C and 5D). Notably, analysis of the anxiety parameters between the groups showed no significant differences ([Figure S4](#mmc1){ref-type="supplementary-material"}F).

Finally, patients with UCDs, including ASLD, have been reported to have an increased propensity to develop seizures ([@bib6], [@bib28], [@bib35], [@bib36]). Because the LC region has a distinct antiepileptic effect in limiting both the spread and duration of seizures ([@bib13], [@bib21], [@bib24], [@bib52]), we tested whether LC-ASL-cKO mice have high seizure sensitivity. By inducing seizures with pentylenetetrazol (PTZ) injections, we found that *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice are significantly more reactive to PTZ-induced seizure as compared to *Asl*^*f/f*^ control mice ([Figure 5](#fig5){ref-type="fig"}E). Furthermore, all *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice developed myoclonic jerks with shorter latency as compared to only half of *Asl*^*f/f*^ control mice ([Figure 5](#fig5){ref-type="fig"}F). Importantly, supplementing NO donors to *Asl*^*f/f*^*;TH Cre*^*+/−*^ mice rescued the LC stereotypical phenotypes of hyper-locomotion and seizure hypersensitivity, giving therapeutic context to our findings ([Figures 5](#fig5){ref-type="fig"}C--5E).

Discussion {#sec3}
==========

Behavioral abnormalities, attention deficit, seizures, and executive dysfunction are well-known manifestations in many subtypes of UCDs. Typically, these have been ascribed to injury caused by hyperammonemia, a classic phenotypic characteristic manifestation of UCDs. However, neuropsychological deficits have been observed in individuals with ASLD who have not experienced documented hyperammonemia. Thus, neuronal deficiency of arginine; neurotoxicity mediated by free radicals as well as by guanidinosuccinate, a metabolite that is generated from oxidation of argininosuccinate; and creatine deficiency have all been hypothesized as causative mechanisms ([@bib4], [@bib6]).

Here, we demonstrate that, in the brain, ASL is prominently expressed in the LC, a highly important brain stem nucleus that has output projections of norepinephrine to multiple regions of the brain. Indeed, LC regulates attention-related functions, from learning and memory to stress. Consequently, LC dysfunction is associated with intellectual disabilities, ADHD-like behavior, seizures, motor problems, and hypertension. In several studies, rare disorders enabled the dissection of consequences caused by a specific genetic alteration from the multiple changes that accompany complex diseases ([@bib16]). Thus, the shared clinical manifestation between patients with ASLD and patients with LC dysfunction intrigued us to study the phenotypic consequences resulting from ASL deficiency in the LC.

Phenotypically, we found that LC loss of ASL in mice alters the stress response as manifested by a persistent locomotor activity and by high blood pressure and increases seizure sensitivity. The higher rates of LC discharges we demonstrate in ASL deficiency mice may result from loss of a local negative feedback of noradrenergic autoreceptors that regulate LC activity ([@bib49]). The increased activity of LC neurons may contribute to the enhanced motility of the LC-ASL-cKO mice in an open field, likely reflecting an exaggerated reaction to stressful stimuli. Indeed, a causal relationship has been demonstrated between LC firing and a general locomotor arousal ([@bib12]). Importantly, we demonstrate that supplementation with NO donors rescue TH levels by increasing nitrosylation, thus normalizing norepinephrine levels. Subsequently, NO donors rescue both the seizure hyperactivity as well as the abnormal stress response.

Previous studies have shown that NO donors can penetrate the blood brain barrier ([@bib25], [@bib44]). Our findings here demonstrating the beneficial response to NO donors in reaction to stressful stimuli are consistent with documented improvement in neurocognitive measures following treatment in a subject with ASLD ([@bib46]). Suggesting, that a better understanding of the role ASL plays in the LC will contribute to the management of ASLD patients and, more broadly, may shed light on the metabolic regulation of other more common LC-related pathologies.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal anti-ASLAbcamCat\# ab97370; RRID:[AB_10680261](nif-antibody:AB_10680261){#intref0010}Sheep polyclonal anti-THMerckmilliporeCat\# AB1542; RRID:[AB_90755](nif-antibody:AB_90755){#intref0015}Rabbit polyclonal anti-THCell SignalingCat\# 2792; RRID:[AB_2303165](nif-antibody:AB_2303165){#intref0020}Mouse monoclonal anti-GAPDHAbcamCat\# ab8245; RRID:[AB_2107448](nif-antibody:AB_2107448){#intref0025}Rabbit monoclonal anti-GAPDHCell Signaling2118; RRID:[AB_561053](nif-antibody:AB_561053){#intref0030}**Bacterial and Virus Strains**Lentiviral pLKO.1 ASL shRNA target gene setDharmaconRHS4533**Biological Samples**Human brain tissue arrayBiomaxNct17N002A48**Chemicals, Peptides, and Recombinant Proteins**PuromycinSigma-AldrichP8833RIPASigma-AldrichR0278Protease inhibitor cocktailCalbiochem539131Opti-MEM® I Reduced Serum MediumThermoFisher Scientific11058021Sodium NitrIte NaNO~2~Sigma-AldrichS2252S-Nitroso-N-acetyl-DL-penicillamine (SNAP)CayMan chemicalsCat\# 82250Alltrans-retinoic acidSigma-AldrichR262512-O-tetradecanoylphorbol 13-acetateSigma-AldrichP8139**Critical Commercial Assays**RNeasy Mini KitQIAGEN74104RNase-Free DNase SetQIAGEN79254SYBR green PCR master mixThermo Fisher scientific4385612BCA Protein Assay KitThermoFisher Scientific23225Purelink RNA micro kitThermoFisher Scientific12183016Viral packaging mixReniumK4975-00**Deposited Data**RNA-seqThis paperGSE138471**Experimental Models: Cell Lines**SH-SY5YATTCCRL-2266**Experimental Models: Organisms/Strains**Mouse: C57BL/6JOlaHsdEnvigoN/AMouse: B6.FVB-Tg(Cdh5-cre)7Mlia/JThe Jackson LaboratoryStock No: 006137Mouse: B6.Cg-Tg(Th-cre)1Tmd/JLaboratory of Dr. Ofer YizharN/AMouse: dTomatoLaboratory of Prof. Alon Chen([@bib40])**Oligonucleotides**Human_HPRT_qPCR \_FThis paperN/AATTGACACTGGCAAAACAATGCHuman_HPRT_qPCR \_RThis paperN/ATCCAACACTTCGTGGGGTCCHuman_ASL_qPCR \_FThis paperN/AATGGCCTCGGAGAGTGGGAAHuman_ASL_qPCR \_RThis paperN/AGCTTTGCTGCCTTGAACATCCAHuman_TH_qPCR \_FThis paperN/ATGTCCACGCTGTACTGGTTCHuman_TH_qPCR \_RThis paperN/ACACCATAGGCCTTCACCTCCHuman_cFOS_qPCR \_FThis paperN/ACTGATACACTCCAAGCGGAGAHuman_cFOS_qPCR \_RThis paperN/ATTGGCAATCTCGGTCTGCAAHuman_VGF_qPCR \_FThis paperN/ATCCCGATCTTCCCCTGTCCHuman_VGF_qPCR \_RThis paperN/AGCCGGAGACAGCTGGTGMouse_HPRT_qPCR \_FThis paperN/AGCAGTACAGCCCCAAAATGGMouse_HPRT_qPCR \_RThis paperN/AGGTTCCTTTTCACCAGCAAGCTMouse_ActB_qPCR \_FThis paperN/ACTGTCCCTGTATGCCTCTGMouse\_ ActB \_qPCR \_RThis paperN/AATGTCACGCACGATTTCCMouse_Asl_qPCR \_FThis paperN/AGAAGGAACTCATCGGTGAAGCTMouse\_ Asl_qPCR \_RThis paperN/ACCTCATCCACAGCCTGAGGTMouse\_ TH \_qPCR \_FThis paperN/AAATACAAGCAGGGTGAGCCAMouse\_ TH \_qPCR \_RThis paperN/ACTTCAGCGTGGCCTATACCTForward primer for Asl *in situ* hybridization\
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Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ayelet Erez (<ayelet.erez@weizmann.ac.il>).

This study did not generate new reagents.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human studies {#sec4.3.1}

The Longitudinal Study of UCDs is an observational natural history study being conducted by the NIH Rare Disease Clinical Research Network's Urea Cycle Disorders Consortium (UCDC). The study, now in its 13^th^ year is conducted at 14 sites in the United States, Canada, Germany, and Switzerland. Clinical, laboratory, patient-reported, and neuropsychological data are collected systematically across all sites according to guidelines outlined in a manual of operations. Informed consent is obtained from all participants prior to enrollment. The study is monitored by an independent data safety monitoring board of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. From this study, we analyzed two sets of data. CNMC protocol number - Pro00000161 -- Longitudinal Study of Urea Cycle Disorders. The first study was the parent- or participant-reported behavioral characteristics in individuals with ASLD and ASS1D. A total of 100 individuals with ASLD (median age 10.9 years, IQR 5.3-21) and 89 individuals with ASS1D (median age 10.2 years, IQR 5.5-16.24) who were enrolled in the study were included in the analyses. The second was attention scores for the CBCL which was administered by certified neuropsychologists or psychological associates. The attention scores from the CBCL were converted to a standardized score where 100 represents the population mean and scores below 85 and above 115 are considered clinically significant. The formulae used for conversion to standardized scores are as follows: for z-score, SS = (z^∗^15)+100; for scaled scores, Z = (ScS-10)/3 and SS = (z^∗^15)+100; for T-scores, z = (T-50)/10 and SS = (z^∗^15)+100. Using longitudinal data, we implemented multiple quantile regression models, accounting for the correlation across multiple assessments per subject, to compare the median scores on CBCL attention scores in individuals with ASLD and ASS1D. At assessment points, the models controlled for the frequency of prior hyperammonemic events, prior incidents of coma or instances of increased intracranial pressure, as well as the peak ammonia level, the maximum length of stay and the current BRIEF Global Executive Composite (GEC) score. Subgroup analysis focused on comparing the same outcomes in individuals with ASLD and ASS1D who never experienced a hyperammonemic event controlling only for the current BRIEF GEC score. All outcomes were represented as standard scores normed to a mean of 100 and a standard deviation of 15. In the study cohort included, for ASLD, 50.00% (63 subjects) were female, 46.83% (59 subjects) were male, and 3.17% (4 subjects) unknown. For ASS1D, 53.98% (61 subjects) were female, 39.82% (45 subjects) were male, and 6.19% (7 subjects) were unknown. These are not different from expected distributions thus there was no bias in any gender selection

### In vivo animal studies {#sec4.3.2}

All animal procedures were approved by the Institutional Animal Care and Use Committee (applications number: 07201118-1) and were performed in strict adherence to Weizmann Institute Animal Care and Use guidelines. Mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). B6.FVB-Tg(Cdh5-cre)7Mlia/J. C57BL/6JOlaHsd mice were purchased from ENVIGO RMS (ISRAEL). The B6.Cg-Tg(Th-cre)1Tmd/J and tdTomato mice were kindly given to us by Dr. Ofer Yizhar and Professor Alon Chen respectively ([@bib40]). Mice were monitored daily by Weizmann Institute staff and veterinary personnel for health and activity. Mice were given *ad libitum* access to water and standard mouse chow with 12-hr light/dark cycles. For the blood pressure experiment of Cdh5-cre mice, animals received arginine free diet (Envigo,TD09152 TEKLAD) from weaning. Experiments were conducted on 8-15-week-old male mice during the dark phase. For the flow cytometry experiments, cells were taken from 20-25 days old mice. Littermates of age and gender matched mice were randomly assigned to experimental groups.

### Cell cultures {#sec4.3.3}

SH-SY5Y human neuroblastoma cells (American Type Culture Collection, ATCC, Manassas, VA, USA) were grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% heat-inactivated FBS, 100 units/mL streptomycin, and 100 μg/mL penicillin at 37°C in a humidified 5% CO2 atmosphere. All cells were tested routinely for mycoplasma using a Mycoplasma EZ-PCR test kit (20--700-20, Biological Industries). The cells were differentiated by treatment with Alltrans-retinoic acid (R2625 Sigma) 0.01M 2 and 4 days after plating, followed by treatment with 80 nM 12-O-tetradecanoylphorbol 13-acetate (TPA, P8139 Sigma), 6 and 8 day after plating.

Method Details {#sec4.4}
--------------

### Transient transfection {#sec4.4.1}

SH-SY5Y cells were seeded in 6-well plates at 200,000 cells/well. At the following day, cells were transfected with 3μg of either control vector (*shGFP*) or siRNA targeted to *ASL* (*shASL*) mRNA (TAMAR laboratory RHS4533). Transfection was done using Lipofectamine® 2000 Reagent (Catalog \#: 11668-019, Invitrogen) in the presence of Opti-MEM® I Reduced Serum Medium (Catalog \#: 31985-062, Invitrogen). 4 hours after transfection, medium was replaced, and experiments were performed starting 48 hours post transfection.

### Virus infection {#sec4.4.2}

HEK293T cells were used to package the lentivirus. HEK293T cells in the logarithmic growth phase were seeded into a 10cm plate. Once cell confluence reached 80%, viral packaging mix (Renium K4975-00) and1μg of either *shGFP* or *shASL* were co-transfected into HEK293T cells with the aid of lipofectamine 2000. 48 h after transfection, the supernatant of HEK293T cells was collected and centrifuged (1000 rpm) at 4°C for 10 min to remove cell debris. SH-SY5Ycells were seeded in 6-well plates (200,000 cells/well) and grown to reach approximately 80% confluency. 0.5ml of the supernatant was added to the cell culture medium without Penicillin-Streptomycin and incubated with the cells for 12 h. In the next day, the medium was replaced by fresh medium. The cells were then transferred to 10cm plate and Puromycin (4 μg/mL) was added for 4 days.

### Human subjects {#sec4.4.3}

Brain tissue arrays were obtained from US BIOMAX, tissue ID: Nct17N002A48.

### Mice perfusion {#sec4.4.4}

Following euthanasia, mice were rapidly perfused with cold 4% PFA in PBS. Mice brains were rapidly removed, immersed in freshly 4% paraformaldehyde for 24 hours, and then transmitted to 1% paraformaldehyde for 24 hours. For *in situ* hybridization mice brains were placed in 1 × PBS with 30% sucrose for another 24 hours and then frozen and sectioned in coronal plane using a microtome. For immunostaining, mouse brains were embedded in paraffin.

### NO treatment {#sec4.4.5}

For *in vitro* assays, either 100 μM S-Nitroso-N-acetyl-DL-penicillamine (SNAP) (CayMan chemicals 82250) was added to the medium 5 minutes before cell collection, or Sodium Nitrite (NaNO~2~) 10mM was added 10 hours before collection. For *in vivo* rescue experiments, mice were treated with NaNO~2~ 100mg/kg in drinking water, renewed every 3 days (Sigma-Aldrich, St. Louis, MO, catalog number S2252).

### Nitrosylation assay {#sec4.4.6}

Detection of protein nitrosylation was performed using the SNO-RAC method ([@bib22]) with minor adjustments. Briefly, cell lysates were prepared, and a total of ∼2 mg protein was used for each experimental condition. The blocking step was performed for 30 min at 50°C, in the presence of 40 mM N-Ethylmaleimide (NEM) with frequent vortexing. After the acetone precipitation step, proteins were recovered by centrifugation at 2000 g for 5 min at 4°C, and the pellets were resuspended in HENS buffer (100 mM HEPES, 1 mM EDTA, 0.1 mM neocuproine, 1% SDS, pH 7.5). This material was added to 100 μL thiopropyl Sepharose beads (GE Healthcare) in the presence of 50 mM sodium ascorbate. Following rotation in the dark overnight at 4°C, the beads were washed with 4 × 1 mL HENS buffer, then 2 × 1 mL HENS/10 buffer (HENS diluted 1:10). Captured proteins were eluted with 30 μL HENS/10 containing 250 mM 2-mercaptoethanol for 20 min at room temperature and analyzed by western blotting.

### Laser micro-dissection (LMD) {#sec4.4.7}

Brain were removed rapidly, briefly washed in cold PBS, embedded and frozen in OCT on dry ice without fixation. 8 μm thick sections were cut from the frozen block, mounted on polyethylene membrane-coated glass slides (Zeiss, A4151909081000), air-dried for 1 m at room temperature and put in −80°C. At the day of the experiment, slides were thawed for 5 minutes in room temperature followed by fixation in 70% ethanol (30 s), incubation in DEPC water, stained with 150μl 1% crystal violet acetate solution (Sigma-Aldrich C5042), and washed vigorously in 100% ethanol for a total of 30 s and air-dried for 3 minutes before microdissection. Tissue sections were microdissected using a UV laser-based PALM Microbeam (Zeiss). The cutting was performed with the following parameters: PALM 40X lens, cut energy 35 (1-100), cut focus 65 (1-100). Tissue fragments were catapulted and collected in 0.2ml adhesive cap tubes (Zeiss, A4151909181000) with these settings: LPC energy 50 (1-100), LPC focus 63 (1-100). The capturing success was visually confirmed by focusing the PALM on the targeted adhesive cap after the collection session. 100 cells were selected for microdissection from the LC of each mouse. Samples from LMD were used for RNA sequencing, RT-PCR and proteomic analysis. For TaqMan probes analysis, RNA was extracted using PureLink RNA Micro Scale Kit (ThermosFisher).

### RNA sequencing {#sec4.4.8}

Samples of 100 lysed cells were amplified separately using SMARTSeq Ultra Low Input RNA V4 kit from (Clontech 634890). After the amplification step (16 cycles), the amplicons were fragmented to fragment sizes of about 300bp using Covaris E220 (Covaris,Inc.,Woburn, MA, USA). The amplified fragments were processed to libraries according to the chip seq protocol as previously described ([@bib7]). Libraries were evaluated by Qubit and TapeStation. Sequencing libraries were constructed with barcodes to allow multiplexing of all samples in one lane. Between 17-20.5 million single-end 60-bp reads were sequenced per sample using Illumina HiSeq 2500 V4 instrument.

### Library construction and sequencing {#sec4.4.9}

Total RNA for each sample, was processed using the SMARTer Ultra Low Input RNA, followed by in-house DNA Seq protocol. Sequencing Libraries were constructed with barcodes to allow multiplexing of 12 samples on 1 lane of Illumina HiSeq machine, using the Single-Read 60 protocol (v4). The output was ∼18.6 million reads per sample. Fastq files for each sample were generated with bcl2fastq-v2.17.1.14.

### Sequence data analysis {#sec4.4.10}

Poly-A/T stretches and Illumina adapters were trimmed from the reads using cutadapt; resulting reads shorter than 40bp were discarded. Reads for each sample, were aligned independently using TopHat2 (v2.0.10) ([@bib32]) against the mouse genome (mm10). Counting proceeded over genes annotated in RefSeq release mm10, using htseq-count (version 0.6.1p1) ([@bib2]). Only uniquely mapped reads were used to determine the number of reads falling into each gene (intersection-strict mode). Differential analysis was performed using DESeq2 package (1.6.3) ([@bib1]). Differentially expressed genes, were determined by a p value of \< 0.05 and absolute fold changes \> 1.5 and max raw counts \> 10.

### Bioinformatics analysis {#sec4.4.11}

Differential expressed (DE) genes were analyzed with the use of Ingenuity Pathways Analysis (Ingenuity® Systems, <https://www.ingenuity.com>) to determine the most significantly relevant biological functions and pathways.

### Telemetry probes implantation {#sec4.4.12}

Probe implantation was preformed according to the manufacturer's instructions ([@bib29]). Briefly, mice were anaesthetized with Ketamine (200 mg/kg BW) and xylazine (10 mg/kg BW). A midline incision was made on the ventral neck. The left common carotid artery was separated and ligated 1--2 mm cranially to its bifurcation. A second ligature was used to suspend the artery 4--5 mm proximal to the site of ligation. Through a small incision in the artery wall, the catheter was advanced 6--7 mm toward the aorta and fixed with sutures. A subcutaneous pocket on the flank of the animal was made with blunt scissors, and the transmitter was inserted therein using a small hemostat. The catheter and the transmitter were fixed in place with acrylic glue and the skin incision was closed with absorbable sutures. Mice were left to recover for 7 days after the surgery followed by 7 days of blood pressure recording. For stress induction, mice were introduced to a retired breeder ICR mouse for 20s and then separated with a barrier for another 24h.

### Seizure Induction {#sec4.4.13}

Pentylenetetrazol (PTZ) was purchased from Sigma (Sigma P6500) and was dissolved in 0.9% NaCl to 3mg/mL. Seizures were induced with i.p. injection of 50mg/kg. Following injection, seizure behavior was followed for 30min. PTZ-induced seizures were classified by a six-point scale as was previously published ([@bib59]). Briefly, stage 0 was defined as no change in the behavior. Stage 1 was defined as hypoactivity, characterized by the animal being in a crouch or prone position with the abdomen fully touching the bottom of the cage. Stage 2 was defined as partial clonus, including that of the face, head, or forelimbs. Stage 3 was defined as generalized clonus, consisting of rearing, falling, and clonus of all four limbs and the tail, but with recovery. Stage 4 was defined as major seizures involving falls and staying down, exhibiting forelimbs that are parallel to the body axis and stiffness. Stage 5 was defined as major seizures involving hyperactivity, followed by a clonus of all four limbs that may end in death.

### Behavioral studies-open field test {#sec4.4.14}

For behavioral tests mice were in a facility with reverse 12h light−dark cycle. All behavioral tests were performed during the dark phase of the cycle, following at least 1h of habituation. Before the restrain stress test, mice were placed in ventilated 50 mL Falcon tubes for 30 minutes. This test was performed as previously described ([@bib57]). Briefly, the apparatus for the open-field test (TSE Systems) consists of a brightly illuminated (120 lux) white Plexiglas box (50 cm × 50 cm × 40 cm). Each mouse was placed in the corner of the apparatus to initiate a 10-min test session. A camera (Eneo model VK1316S) mounted above the apparatus, transmitted images of the mouse that were analyzed by VideoMot2 software (TSE Systems). Locomotion in the box was quantified using a video tracking system.

### Brain tissue biopsies collection {#sec4.4.15}

Immediately after decapitation, mouse brains were removed and placed in 1.0 mm coronal slice intervals brain matrix (BSMAS001-1 Civic Instruments). The brains were sliced using standard razor blades into 2-mm slices that were frozen immediately on dry ice. The areas of interest were punched using a microdissecting 16G needle according to the anatomical references of The Mouse Brain in Stereotaxic Coordinates ([@bib100]). The brains were stored immediately at−80°C for later use.

### Catecholamine measurements {#sec4.4.16}

Monoamines were extracted from the brain structures using 0.1 M perchloric acid. The extracts were assayed for Norepinephrine (NE), 3-Methoxy-4-hydroxyphenylglycol (MHPG), dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) using reverse-phase high-performance liquid chromatography (RP-HPLC) with electrochemical detection (UltiMate3000/CoulochemIII; Thermo Fisher) using citrate-phosphate buffer (containing 6% acetonitrile 1% methanol, pH 4) as the mobile phase ([@bib3]). Monoamines were separated on an analytical column (C18, 150 mm × 3 mm, 3 μm; Triart, YMC Europe) at a flow rate of 0.5 ml/min and detected at +220 mV and +350 mV. The detection limit for all compounds of interest was between 0.032 and 0.050 nM. Peak areas were used to calculate monoamine concentrations by reference to an external standard curve. Monoamine tissue contents were reported as micromoles per milligram of protein (the protein concentration of extracts was determined by the BCA method).

### Immunostaining {#sec4.4.17}

*In-vivo*: Four-micrometer paraffin embedded tissue sections were deparaffinized by xylene and rehydrated through a gradient of ethanol. Sections were exposed to acetone for 7 min at −20°C and antigens were retrieved in citric acid in a microwave oven at full-intensity for 3 min until boiling point was reached, and then at 20% intensity for 10 min. Blocking of nonspecific binding was done with 20% normal horse serum and 0.2%--0.5% triton for 90 min in a humidity chamber. Sections were incubated with the primary antibodies as follow; ASL (1:100, Abcam, ab97370); TH (1:500, millipore AB1542). All antibodies were diluted in PBS containing 2% normal horse serum and 0.2% Triton. Sections were incubated overnight at RT followed by 48h at 4°C. Sections were washed three times in PBS and incubated with biotinylated anti-rabbit antibody for 90 min in a humidity chamber, washed, and incubated with streptavidin Cy2 and Cy3 anti-goat antibody (all from Jackson ImmunoResearch) for 40 min. Sections were counterstained by Hoechst (Molecular Probes). Stained sections were examined and photographed with a fluorescence microscope (Eclipse Ni-U; Nikon) equipped with Plan Fluor objectives (20x;40x) connected to a color camera (DS-Ri1, Nikon) microscope.

The fluorescence intensity quantification for the expression of TH was done blindly to the genotype using imageJ software.

### Protein analysis: western blotting {#sec4.4.18}

Cells were lysed in RIPA and 1:100 protease inhibitor (Sigma-Aldrich). After centrifugation, the supernatant was collected, and protein content was evaluated by the BCA protein assay kit (Thermo Fisher 23225). 80μg of each sample under reducing conditions were loaded into each lane and separated by electrophoresis on a 10% SDS polyacrylamide gel. Following electrophoresis, proteins were transferred to Immobilon transfer membranes (Tamar). Non-specific binding was blocked by incubation with 5% milk in TBST (10 mM Tris--HCl (pH 8.0), 150 mM NaCl, 0.1% Tween 20) for 1 h at 25°C. Membranes were subsequently incubated with antibodies against ASL (1:500, ab97370, Abcam), p97 (1:10,000, PA5-22257, Thermo Scientific), GAPDH (1:1,0000, ab128915, Abcam), TH (1:500, CST-2792S, cell signaling). Antibody was detected using peroxidase-conjugated AffiniPure goat anti-rabbit IgG or goat anti-mouse IgG (Jackson ImmunoResearch) and enhanced using chemiluminescence western blotting detection reagents (Pierce ECL Western Blotting Substrate, Thermo Fisher). Gels were quantified by Gel Doc XR+ (BioRad) and analyzed by ImageLab 6.0 software (BioRad). The band area was calculated by the intensity of the band divided by the value obtained from the loading control.

### RNA extraction and complementary DNA (cDNA) synthesis {#sec4.4.19}

RNA was extracted from cells using RNeasy Mini Kit (74104, QIAGEN). cDNA was synthesized from 1 μg RNA by using qScript cDNA Synthesis Kit (Quanta). Quantitative PCR was performed using SYBR green PCR master mix (Thermo Fisher scientific 4385612) or with TaqMan Real-Time PCR Master Mix (Thermo Fisher scientific 4444557). Primer sequences are summarized in the [STAR Methods](#sec4){ref-type="sec"}' [Key Resources Table](#sec4.1){ref-type="sec"}.

### *In situ* hybridization {#sec4.4.20}

*In situ* hybridization procedures and probes were used as previously described ([@bib37]) with minor adjustments. Briefly, 500 base pair Antisense and sense (control) RNA probes were generated using *Asl* cDNA from mouse liver. The probe was designed to overlap the floxed region of the gene. The PCR products were cleaned by QIAquick PCR Purification Kit. The probe was incorporated into a plasmid containing T7/T3/SP6 RNA polymerase and transformed into DH5α competent cells. Following mini-prep, the DNA was sequenced to confirm insert identity and orientation. The plasmids were then linearized by PstI (antisense) and NcoI (sense) and following DNase treatment and purification, were added to the hybridization buffer.

### Proteomic analysis {#sec4.4.21}

Samples from 100 cells collected from the LMD were digested by trypsin and analyzed by LC-MS/MS on Q Exactive plus (Thermo). The data was analyzed with MaxQuant 1.5.2.8 versus the Mouse Uniprot database. Data was analyzed using the same software. The identifications were filtered for proteins identified with FDR \< 0.01 and that appeared in at least three samples in one group. As the proteins amount was low, identifications based on single peptides were not filtered out.

### Flow cytometry for NO measurements {#sec4.4.22}

Dissections were performed on young mice (P20-P25) crossed with *Ai9*^*f/f*^*; TH Cre*^*+/−*^or *Ai9;Asl*^*f/f*^*; TH Cre*^*+/−*^mice. Single cell suspensions was made from mouse brain-stem region by enzymatic digestion with Papain Dissociation System (Worthington Biochemical) as was previously described ([@bib19]). The cells were then analyzed by polychromatic flow cytometry. Data was acquired on an LSRII (BD Biosciences) and analyzed using BD FACSDiva 6 (version 7.6.5). Intracellular NO was detected by incubation of cells for 15 min at 37°C with 10 μM DAF-FM diacetate followed by extensive washing, according to the manufacturer's instructions (Molecular Probes).

### Electrophysiology {#sec4.4.23}

Mice were rapidly decapitated, and the brains were removed and placed in 4°C low sodium sucrose-based cutting solution, containing (in mM): 2.5 KCl, 16 NaHCO3, 1.25 NaH2PO4, 10 glucose, 10 MgSO4, 0.5 CaCl2 and 234 sucrose. 350 um coronal slices containing the LC region were prepared in the same solution using a vibro-slicer. Slices were then transferred into ACSF containing (in mM): 124 NaCl, 2.5 NaH2PO4, 26 NaHCO3, 2.7 MgSO4, 2.7 KCl, 19 glucose, 2 ascorbic acid and incubated at 37°C for 45 minutes. Following incubation, slices were kept and recorded at room temperature. Slices and solutions were constantly carbogenated (5% CO2 and 95% O2). Slices were then transferred to a recording chamber placed on the stage of an Olympus BX51WI upright microscope and perfused with ACSF at approximately 1.5mL/min. Single LC neurons were visualized using infrared Nomarski optics and recorded with patch pipettes containing (in mM): 136 K-gluconate, 10 KCl, 5 NaCl, 10 HEPES, 0.1 EGTA, 0.3 Na-GTP, 1 Mg-ATP, and 5 phosphocreatine, pH 7.2, having a resistance of 5--10 MOhm. Signals were amplified with Axopatch 200A and recorded with PClamp-10 (Axon Instruments). Data was analyzed offline using Clampfit 10, MATLAB R2017b and Microsoft Excel 2016.

Spikes (threshold, peak and after hyperpolarization) were detected using a homemade script based on numerical derivative. Spike characteristics were obtained from average of over 10 spikes per recording, aligned at peak. After hyperpolarization, recovery slope was calculated as a maximal change over 3ms period in 80ms window after the peak. Inter spike intervals (ISI) were calculated as distances between consecutive spike peaks. Histograms were constructed with a step calculated from the 1^st^ and 3^rd^ quartiles of ISI distributions and aligned at mean ISI, averaged histogram is presented in [Figure 5](#fig5){ref-type="fig"}.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Unless indicated otherwise, values are expressed as mean ± SEM. Statistical analysis was performed by Weizmann statistician using repeated-measures two-way ANOVA with Bonferroni post hoc t tests or Student's t tests as appropriate. Statistical details of individual experiments such as exact values of n can be found in the figures and legends. The sample size was chosen in advance based on common practice of the described experiment, and is mentioned for each experiment. Each experiment was conducted with biological and technical replicates and repeated at least three times unless specified otherwise. Statistical tests were done using Prism software (GraphPad Software). p \< 0.05 was considered significant in all analyses (^∗^ denotes p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005, ^∗∗∗∗^ p \< 0.0001).

Data and Code Availability {#sec4.6}
--------------------------

The RNA sequencing data are published with Gene Expression Omnibus (GEO). The accession number is GEO: [GSE138471](ncbi-geo:GSE138471){#intref0060}
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